Dx&Vx Advances Global Out-Licensing Talks for First-in-Class Oral Obesity Drug and Cancer Vaccine at BIO 2026
Key Insights
Dx&Vx (search) held partnering meetings with over 40 global pharmaceutical and biotech companies at BIO International Convention 2026 in San Diego from June 22–25.
The company's oral obesity (search) drug candidate, described as the world's first irreversible GLP-1 receptor agonist (search), drew strong interest and multiple follow-up meetings.
Anti-cancer candidate OVM-200 attracted expanded global discussions following successful Phase 1 results presented at the ASCO Annual Meeting in May.
Dx&Vx (search) (KOSDAQ: 180400), a South Korea-based medical diagnostics and drug development company, has significantly advanced its global business development efforts, conducting partnering meetings with more than 40 pharmaceutical and biotechnology companies at the BIO International Convention 2026 in San Diego. The event, held from June 22 to 25, is the world's largest biotechnology business gathering, attracting over 20,000 participants from pharmaceutical companies and investment institutions worldwide for discussions on technology transfer, joint development, and strategic investment.
During a 13-minute corporate presentation, CEO Kevin Kwon showcased the company's key pipelines, generating strong responses from attendees. The presentation covered Dx&Vx (search)'s anti-cancer drug candidate OVM-200, its oral obesity (search) drug candidate, and the nucleic acid/LNP stabilization platform (KRNA), along with two pipelines from subsidiary Avixgen (search): a dry eye disease (search) treatment candidate (AVI-4015) and a blood–brain barrier penetration platform (ACP).
Oral Obesity (search) Drug: A World-First Mechanism
The company's oral obesity (search) drug candidate emerged as one of the most compelling assets at the convention. Dx&Vx (search) introduced the compound as "the world's first irreversible GLP-1 receptor agonist (search)," a mechanism that the company is developing alone worldwide. According to the company, the differentiated efficacy profile of this irreversible approach attracted considerable attention from potential partners, leading to multiple follow-up partnering meetings during and after the event.
OVM-200 Builds on ASCO Momentum
The anti-cancer vaccine candidate OVM-200 also drew especially strong interest from global partners. This enthusiasm built on the successful Phase 1 clinical results that UK-based associate Oxford VacMedix (search) presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in May. Following that data presentation, follow-up discussions expanded rapidly at BIO USA, signaling growing confidence in the program's clinical potential.
Out-Licensing Within Reach
Reflecting on the meetings, CEO Kevin Kwon stated, "The results of our meetings with over 40 companies, including major pharmaceutical companies, are quite promising." He added, "As our overseas out-licensing outcomes take shape, the company will maintain focus and momentum through to signing."
The breadth of partnering interest across Dx&Vx (search)'s pipeline—spanning oncology, metabolic disease, and platform technologies—positions the company for potential near-term licensing transactions as discussions progress toward formal agreements.